Singapore: HSA Moves Toward an Integrated Health Regulatory Framework

Regulatory Update | October 2026

Singapore is moving toward a more integrated health-regulatory system one that could reshape how healthcare companies, medical-device manufacturers, and other industry stakeholders interact with regulators.

On 9 September 2026, Singapore's Health Sciences Authority (HSA) announced that the Health Sciences Authority (Amendment) and Other Matters Bill had been tabled for Second Reading in Parliament. The bill would consolidate health-regulatory functions currently spread across the Ministry of Health (MOH), HSA, and the Secretariat supporting the healthcare Professional Boards.

This comes as healthcare technologies increasingly cross traditional regulatory boundaries particularly in digital health, genomics, and AI. For companies operating in or entering Singapore, the development matters both for its institutional implications and because HSA continues to update its medical-device framework in parallel.

What's Changing?

Singapore's healthcare regulatory ecosystem currently spans several institutions:

• MOH: healthcare services, health information, human biomedical research, biosafety

• HSA: health products, including medicines and medical devices

• Professional Boards Secretariat: supports Boards and Councils overseeing healthcare professionals

The proposed legislation would bring these capabilities closer together under HSA, which would take on:

• Administration and regulation of the Human Biomedical Research Act

• Administration and regulation of the Biological Agents and Toxins Act

• Specified regulatory and enforcement functions under selected MOH legislation

• Functions currently performed by the Professional Boards Secretariat

Professional Boards and Councils would retain their existing self-regulatory and disciplinary roles.

A Two-Phase Rollout

Phase Timeline What Moves

Phase 1 November 2026 MOH's Health Regulation Group functions and manpower transition to HSA

Phase 2 By end of 2027 Professional Boards Secretariat functions and manpower transition to HSA

Important: these are proposed and planned changes still moving through the legislative process. Distinguish between the announced direction of reform and requirements already in force today.

Why Is Singapore Consolidating These Functions?

Healthcare is getting more complex. New technologies and care models can span multiple regulatory areas at once a single product might raise questions about medical devices, healthcare services, biomedical research, health information, and professional practice simultaneously.

That overlap can mean companies end up navigating more than one regulatory body for a single innovation. The integrated model aims to provide a more coordinated regulatory interface and greater clarity and predictability for industry.

For companies, this could eventually mean a more connected regulatory journey, from R&D through clinical application to healthcare delivery.

What This Means for Medical-Device Companies

HSA already regulates medical devices under Singapore's Health Products Act and Health Products (Medical Devices) Regulations 2010. Companies generally need the appropriate dealer's licence before manufacturing, importing, or supplying devices, and devices typically require registration before supply (subject to exemptions, such as Class A low-risk devices).

The restructuring doesn't replace these existing requirements; it signals a move toward closer coordination across the broader health-regulatory landscape. For manufacturers, this makes regulatory planning across the entire product lifecycle increasingly important not just at the point of registration.

HSA's September Guidance Update

Alongside the institutional reform, HSA updated its medical-device guidance on 10 September 2026, now listing GN-15-R14 Guidance on Medical Device Product Registration (2026 Sep), along with updated templates covering authorisation letters, marketing history, safety declarations, labelling, adverse-event, and field-safety-corrective-action declarations.

Other 2026 updates include:

• GN-21-R7 : Guidance on Change Notification for Registered Medical Devices (July 2026, annex updated August)

• Updated guidance on grouping medical devices (June 2026)

The takeaway: Singapore's regulatory framework continues to evolve even as the broader institutional restructuring unfolds. Don't wait for the big picture to settle before keeping your documentation current.

A More Connected Regulatory Environment

This consolidation could matter most for innovative products that don't fit neatly into one regulatory category digital health, AI-enabled products, and biomedical innovations often involve overlapping considerations across products, research, services, and professional practice.

What this could mean for industry over time:

• Greater coordination : a clearer central regulatory interface for activities spanning multiple health-regulatory areas

• More predictable engagement : improved clarity around licensing, enquiries, and regulatory interactions

• Closer lifecycle alignment : more connected regulatory considerations from R&D through clinical use and delivery

• Greater importance of early planning : companies developing innovative technologies may need to consider multiple regulatory dimensions earlier, not treat registration as a standalone step

ARQon Insight

Singapore's proposed consolidation reflects a broader trend: regulators are increasingly adapting their structures to technologies that cross traditional regulatory boundaries.

For medical-device and life-sciences companies, this means regulatory strategy can't always be separated into individual approval processes. Understanding how different requirements interact is becoming just as important as understanding each one individually especially for products spanning digital health, AI, biomedical research, or other cross-domain technologies.

The proposed HSA model aims to create a more coherent system while maintaining Singapore's focus on patient safety and timely access to beneficial innovation.

What Companies Should Do Now

1. Monitor the transition : follow HSA and MOH announcements as the November 2026 Phase 1 transition approaches.

2. Review your regulatory map : identify which Singapore authorities currently oversee your products and activities, and whether functions may shift under the new structure.

3. Keep submissions current: work from the latest HSA guidance, not older registration document versions.

4. Review change-management processes: ensure internal procedures reflect HSA's latest change-notification requirements.

5. Plan across the full lifecycle: for innovative products, factor in development, clinical evidence, registration, manufacturing, importation, distribution, and post-market surveillance together.

Key Takeaway

Singapore is preparing for a significant reorganization of its health-regulatory functions. The proposed Health Sciences Authority (Amendment) and Other Matters Bill would establish HSA as Singapore's integrated health regulator, with Phase 1 planned for November 2026 and Phase 2 expected by end of 2027.

Meanwhile, HSA continues refining its medical-device guidance including September 2026's product-registration update.

For companies operating in Singapore, staying ahead of both the institutional changes and the ongoing guidance updates will be essential for maintaining regulatory readiness.

Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.

Source

Singapore Health Sciences Authority (HSA) ; Health Sciences Authority (Amendment) and Other Matters Bill; Integrated Health Regulatory System; Medical Device Guidance Documents.